ENDRA Life Sciences Inc.
NDRA
$4.87
$0.020.41%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -98.57% | -30.19% | -18.30% | 75.02% | -76.25% |
| Total Depreciation and Amortization | 0.25% | 20.12% | -28.07% | -1.72% | -14.07% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 276.65% | 1,443.07% | 108.20% | -113.70% | 171.89% |
| Change in Net Operating Assets | -74.23% | -136.74% | 128.57% | -89.06% | 191.42% |
| Cash from Operations | -38.46% | -4.52% | 13.87% | 14.69% | 8.54% |
| Capital Expenditure | -- | -- | 100.00% | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | 100.00% | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 2,963.55% | -82.56% | 488.07% | -88.96% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -200.00% |
| Cash from Financing | 2,963.55% | -82.56% | 488.07% | -- | -100.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 96.88% | -295.83% | 77.99% | 23.16% | 8.44% |